CSPC Innovation Pharmaceutical Co Ltd Class A
CSPC Innovation Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of biopharmaceuticals, functional foods, and raw materials in China and internationally. It offers functional raw ingredients, including caffeine, acarbose, anhydrous glucose, theophylline, aminophylline, dihydroxyphylline, theobromine, pentoxifylline, doxofylline, and biological enzymes; and h… Read more
CSPC Innovation Pharmaceutical Co Ltd Class A (300765) - Total Liabilities
Latest total liabilities as of September 2025: CN¥2.05 Billion CNY
Based on the latest financial reports, CSPC Innovation Pharmaceutical Co Ltd Class A (300765) has total liabilities worth CN¥2.05 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CSPC Innovation Pharmaceutical Co Ltd Class A - Total Liabilities Trend (2014–2024)
This chart illustrates how CSPC Innovation Pharmaceutical Co Ltd Class A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
CSPC Innovation Pharmaceutical Co Ltd Class A Competitors by Total Liabilities
The table below lists competitors of CSPC Innovation Pharmaceutical Co Ltd Class A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Landis+Gyr Group AG
OTCGREY:LGYRF
|
USA | $1.09 Billion |
|
ISA ENERGIA BRASIL
SA:ISAE3
|
Brazil | R$25.76 Billion |
|
Co-Tech Development
TWO:8358
|
Taiwan | NT$1.91 Billion |
|
Innoviva Inc
NASDAQ:INVA
|
USA | $462.32 Million |
|
XiaMen HongXin Electron-tech Co Ltd
SHE:300657
|
China | CN¥6.04 Billion |
|
Veris Residential Inc
NYSE:VRE
|
USA | $1.51 Billion |
|
Transcend Information Inc
TW:2451
|
Taiwan | NT$3.21 Billion |
|
Orora Ltd
AU:ORA
|
Australia | AU$1.95 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down CSPC Innovation Pharmaceutical Co Ltd Class A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CSPC Innovation Pharmaceutical Co Ltd Class A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CSPC Innovation Pharmaceutical Co Ltd Class A (2014–2024)
The table below shows the annual total liabilities of CSPC Innovation Pharmaceutical Co Ltd Class A from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.53 Billion | +180.05% |
| 2023-12-31 | CN¥544.96 Million | -14.83% |
| 2022-12-31 | CN¥639.84 Million | +141.05% |
| 2021-12-31 | CN¥265.44 Million | -0.96% |
| 2020-12-31 | CN¥268.00 Million | -38.68% |
| 2019-12-31 | CN¥437.06 Million | +11.65% |
| 2018-12-31 | CN¥391.45 Million | +8.09% |
| 2017-12-31 | CN¥362.16 Million | -8.70% |
| 2016-12-31 | CN¥396.66 Million | +20.13% |
| 2015-12-31 | CN¥330.20 Million | +12.06% |
| 2014-12-31 | CN¥294.66 Million | -- |